Autolus Therapeutics Stock Fundamentals
| AUTL Stock | USD 2.84 0.04 1.43% |
Autolus Therapeutics fundamentals help investors to digest information that contributes to Autolus Therapeutics' financial success or failures. It also enables traders to predict the movement of Autolus Stock. The fundamental analysis module provides a way to measure Autolus Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Autolus Therapeutics stock.
At this time, Autolus Therapeutics' Interest Expense is quite stable compared to the past year. Total Revenue is expected to rise to about 2 M this year, although the value of Gross Profit will most likely fall to (5.1 M). Autolus | Select Account or Indicator |
Autolus Therapeutics Company Shares Outstanding Analysis
Autolus Therapeutics' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Autolus Therapeutics Shares Outstanding | 266.12 M |
Most of Autolus Therapeutics' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Autolus Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Autolus Shares Outstanding Historical Pattern
Today, most investors in Autolus Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Autolus Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's shares outstanding growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Autolus Therapeutics shares outstanding as a starting point in their analysis.
Autolus Therapeutics Shares Outstanding |
| Timeline |
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Autolus Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
Based on the latest financial disclosure, Autolus Therapeutics has 266.12 M of shares currently outstending. This is 47.41% higher than that of the Biotechnology sector and 149.05% higher than that of the Health Care industry. The shares outstanding for all United States stocks is 53.46% higher than that of the company.
Autolus Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Autolus Therapeutics's current stock value. Our valuation model uses many indicators to compare Autolus Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Autolus Therapeutics competition to find correlations between indicators driving Autolus Therapeutics's intrinsic value. More Info.Autolus Therapeutics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Autolus Therapeutics' Return On Equity is quite stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Autolus Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Autolus Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Autolus Therapeutics' direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Autolus Therapeutics could also be used in its relative valuation, which is a method of valuing Autolus Therapeutics by comparing valuation metrics of similar companies.Autolus Therapeutics is currently under evaluation in shares outstanding category among its peers.
Autolus Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Autolus Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Autolus Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Autolus Fundamentals
| Return On Equity | -0.82 | ||||
| Return On Asset | -0.22 | ||||
| Operating Margin | (21.14) % | ||||
| Current Valuation | 140.3 M | ||||
| Shares Outstanding | 266.12 M | ||||
| Shares Owned By Insiders | 18.08 % | ||||
| Shares Owned By Institutions | 76.21 % | ||||
| Number Of Shares Shorted | 7.19 M | ||||
| Price To Earning | (19.33) X | ||||
| Price To Book | 1.56 X | ||||
| Price To Sales | 74.90 X | ||||
| Revenue | 1.7 M | ||||
| Gross Profit | (130.86 M) | ||||
| EBITDA | (156.77 M) | ||||
| Net Income | (208.38 M) | ||||
| Cash And Equivalents | 216.44 M | ||||
| Cash Per Share | 2.38 X | ||||
| Total Debt | 52.97 M | ||||
| Debt To Equity | 0.08 % | ||||
| Current Ratio | 7.29 X | ||||
| Book Value Per Share | 1.79 X | ||||
| Cash Flow From Operations | (145.59 M) | ||||
| Short Ratio | 5.68 X | ||||
| Earnings Per Share | (1.22) X | ||||
| Target Price | 10.45 | ||||
| Number Of Employees | 463 | ||||
| Beta | 2.04 | ||||
| Market Capitalization | 755.79 M | ||||
| Total Asset | 375.38 M | ||||
| Retained Earnings | (878.56 M) | ||||
| Working Capital | 230.56 M | ||||
| Current Asset | 102.22 M | ||||
| Current Liabilities | 6.46 M | ||||
| Net Asset | 375.38 M |
About Autolus Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Autolus Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Autolus Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Autolus Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | -4.6 M | -4.4 M | |
| Total Revenue | 1.7 M | 2 M | |
| Cost Of Revenue | 6.6 M | 6.2 M | |
| Stock Based Compensation To Revenue | 6.60 | 11.48 | |
| Sales General And Administrative To Revenue | 26.88 | 35.90 | |
| Research And Ddevelopement To Revenue | 88.33 | 73.55 | |
| Capex To Revenue | 6.47 | 8.78 | |
| Revenue Per Share | 0.01 | 0.01 | |
| Ebit Per Revenue | (114.86) | (120.60) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Autolus Therapeutics Piotroski F Score and Autolus Therapeutics Altman Z Score analysis. For more information on how to buy Autolus Stock please use our How to buy in Autolus Stock guide.You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Autolus Therapeutics. If investors know Autolus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Autolus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.22) | Revenue Per Share 0.043 | Quarterly Revenue Growth 6.81 | Return On Assets (0.22) | Return On Equity (0.82) |
The market value of Autolus Therapeutics is measured differently than its book value, which is the value of Autolus that is recorded on the company's balance sheet. Investors also form their own opinion of Autolus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Autolus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Autolus Therapeutics' market value can be influenced by many factors that don't directly affect Autolus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Autolus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Autolus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Autolus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.